Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update

RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeksRLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025Streamlined operations and CHF 15.1 million cash reserves expected …
Jetzt den vollständigen Artikel lesen